Shots:
- The companies collaborated to develop the personalized medicines for patients with ultra-rare diseases. The collaboration involves additional resources, financial contribution, and experience from both the company
- The alliance strengthens n-Lorem’s mission to bring immediate hope and rapid treatment to ultra-rare disease patients in need
- n-Lorem Foundation provides a free and lifetime supply of ASO medicines to patients who have diseases caused by extremely rare mutations (1 to 30 patients) globally
Click here to read full press release/ article | Ref: BusinessWire | Image: PRNewswire
The post Ultragenyx Collaborates with n-Lorem Foundation to Advance Personalized Medicines Treatment for Patients with Ultra-Rare Diseases first appeared on PharmaShots.
